Global health therapeutics is a rapidly emerging facet of postgenomics medicine. In this connection, Brucella melitensis is an intracellular bacterium that causes the zoonotic infectious disease, brucellosis. Presently, no licensed vaccines are available for human brucellosis. Here, we report the identification of potential vaccine candidates against B. melitensis using a reverse vaccinology approach. Based on a systematic screening of exoproteome and secretome of B. melitensis 16M, we identified eight proteins as potential vaccine candidates, including LPS-assembly protein LptD, a polysaccharide export protein, a cell surface protein, heme transporter BhuA, flagellin FliC, 7-alpha-hydroxysteroid dehydrogenase, immunoglobulin-binding protein EIBE, and hemagglutinin. Among these, the roles of BhuA and hemagglutinin in the virulence of Brucella are essential to establish infection. Roles of other proteins in the virulence are yet to be studied. Prediction of protein–protein interactions revealed that these proteins can interact with other proteins involved in virulence, secretion system, metabolism, and transport. From these eight potential vaccine candidates, we predicted three surface exposed novel antigenic epitopes that can induce both B-cell and T-cell immune responses. These peptides can be used for the development of either exclusive peptide vaccines or multi-component vaccines against human brucellosis. Reverse vaccinology is an important strategy for discovery of novel global health therapeutics.
Get full access to this article
View all access options for this article.
References
1.
Avila-CalderónED, Lopez-MerinoA, SriranganathanN, BoyleSM, and Contreras-RodríguezA. (2013). A history of the development of Brucella vaccines. Biomed Res Int, 2013, 743509.
2.
BarhD, MisraAN, KumarA, and VascoA. (2010). A novel strategy of epitope design in Neisseria gonorrhoeae. Bioinformation, 5, 77.
3.
BarhD, BarveN, GuptaK, et al. (2013). Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One, 8, e52773.
4.
ButtAM, NasrullahI, TahirS, and TongY. (2012). Comparative genomics analysis of Mycobacterium ulcerans for the identification of putative essential genes and therapeutic candidates. PLoS One, 7, e43080.
5.
CassataroJ, EsteinSM, PasquevichKA, et al. (2005). Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun, 73, 8079–8088.
6.
DandaraC, HuzairF, Borda-RodriguezA, ChirikureS, OkpechiI, WarnichL, and MasimirembwaC. (2014). H3Africa and the African life sciences ecosystem: Building sustainable innovation. OMICS, 18, 733–739.
7.
den HartighAB, RolánHG, de JongMF, and TsolisRM. (2008). VirB3 to VirB6 and VirB8 to VirB11, but not VirB7, are essential for mediating persistence of Brucella in the reticuloendothelial system. J Bacteriol, 190, 4427–4436.
8.
DimitrakopoulouK, DimitrakopoulosGN, SgarbasKN, and BezerianosA. (2014). Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment. OMICS, 18, 15–33.
9.
DoytchinovaIA, and FlowerDR. (2007). VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformat, 8, 4.
10.
EL-ManzalawyY, DobbsD, and HonavarV. (2008). Predicting linear B-cell epitopes using string kernels. J Mol Recognit, 21, 243–255.
11.
FichtTA, Kahl-McDonaghMM, Arenas-GamboaAM, and Rice-FichtAC. (2009). Brucellosis: The case for live, attenuated vaccines. Vaccine, 27, D40–D43.
12.
FincoO, FrigimelicaE, BuricchiF, et al. (2011). Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci USA, 108, 9969–9974.
13.
FrancoMP, MulderM, GilmanRH, and SmitsHL. (2007). Human brucellosis. Lancet Infect Dis, 7, 775–786.
14.
FridleyBL, AboR, TanXL, JenkinsGD, BatzlerA, MoyerAM, BiernackaJM, and WangL. (2014). Integrative gene set analysis: Application to platinum pharmacogenomics. OMICS, 18, 34–41.
15.
GargA, and GuptaD. (2008). VirulentPred: A SVM based prediction method for virulent proteins in bacterial pathogens. BMC Bioinformat, 9, 62.
16.
GasteigerE, HooglandC, GattikerA, DuvaudS, WilkinsMR, AppelRD, and BairochA. (2005). Protein identification and analysis tools on the ExPASy Server. In: JohnM. Walker (ed). The Proteomics Protocols Handbook, Humana Press, pp. 571–607.
17.
GishW, and StatesDJ. (1993). Identification of protein coding regions by database similarity search. Nat Genet, 3, 266–272.
18.
GoelD, and BhatnagarR. (2012). Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544. Mol Immunol, 51, 159–168.
19.
GomezG, PeiJ, MwangiW, AdamsLG, Rice-FichtA, and FichtTA. (2013). Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach. PLoS One, 8, e59751.
20.
GuanP, DoytchinovaIA, ZygouriC, and FlowerDR. (2003). MHCPred: A server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res, 31, 3621–3624.
21.
HeY. (2012). Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. Front Cell Infect Microbiol, 2, 2.
22.
KelleyLA, MezulisS, YatesCM, WassMN, and SternbergMJ. (2015). The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc, 10, 845–858.
23.
KroghA, LarssonB, Von HeijneG, and SonnhammerEL. (2001). Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J Mol Biol, 305, 567–580.
24.
LuceroNE, AyalaSM, EscobarGI, and JacobNR. (2008). Brucella isolated in humans and animals in Latin America from 1968 to 2006. Epidemiol Infect, 136, 496–503.
25.
LuoH, LinY, GaoF, ZhangCT, and ZhangR. (2014). DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res, 42, D574–D580.
26.
MayroseI, PennO, ErezE, et al. (2007). Pepitope: Epitope mapping from affinity-selected peptides. Bioinformatics, 23, 3244–3246.
27.
MeyerME, and MorganWJB. (1973). Designation of neotype strains and of biotype reference strains for species of the genus Brucella Meyer and Shaw. Int J Syst Bacteriol, 23, 135–141.
28.
McMurryJA, KimballS, LeeJH, et al. (2007). Epitope-driven TB vaccine development: A streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med, 7, 351–368.
29.
NancyYY, WagnerJR, LairdMR, et al. (2010). PSORTb 3.0: Improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics, 26, 1608–1615.
30.
NazA, AwanFM, ObaidA, MuhammadSA, ParachaRZ, AhmadJ, and AliA. (2015). Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: A reverse vaccinology based approach. Infect Genet Evol, 32, 280–291.
31.
PappasG, PapadimitriouP, AkritidisN, ChristouL, and TsianosEV. (2006). The new global map of human brucellosis. Lancet Infect Dis, 6, 91–99.
32.
PaulleyJT, AndersonES, and RoopRM. (2007). Brucella abortus requires the heme transporter BhuA for maintenance of chronic infection in BALB/c mice. Infect Immun, 75, 5248–5254.
33.
PaulsenIT, SeshadriR, NelsonKE, et al. (2002). The Brucella suis genome reveals fundamental similarities between animal and plant pathogens and symbionts. Proc Natl Acad Sci USA, 99, 13148–13153.
34.
PerkinsSD, SmitherSJ, and AtkinsHS. (2010). Towards a Brucella vaccine for humans. FEMS Microbiol Rev, 34, 379–394.
35.
PerryQL, HagiusSD, WalkerJV, and ElzerPH. (2010). Evaluating the virulence of a Brucella melitensis hemagglutinin gene in the caprine model. Vaccine, 28, F6–F11.
SahuJ, SenP, ChoudhuryMD, DehuryB, BarooahM, ModiMK, and TalukdarAD. (2014). Rediscovering medicinal plants' potential with OMICS: Microsatellite survey in expressed sequence tags of eleven traditional plants with potent antidiabetic properties. OMICS, 18, 298–309.
38.
SchurigGG, SriranganathanN, and CorbelMJ. (2002). Brucellosis vaccines: Past, present and future. Vet Microbiol, 90, 479–496.
39.
SinghH, and RaghavaGP. (2001). ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 17, 1236–1237.
40.
SinghH, and RaghavaGP. (2003). ProPred1: Prediction of promiscuous MHC Class-I binding sites. Bioinformatics, 19, 1009–1014.
41.
SundaramurthiJC, BrindhaS, ShobithaSR, SwathiA, RamanandanP, and HannaLE. (2012). In silico identification of potential antigenic proteins and promiscuous CTL epitopes in Mycobacterium tuberculosis. Infect Genet Evol, 12, 1312–1318.
42.
SzklarczykD, FranceschiniA, WyderS, et al. (2015). STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 43, D447–452.
43.
TerwagneM, FeroozJ, RolánHG, et al. (2013). Innate immune recognition of flagellin limits systemic persistence of Brucella. Cell Microbiol, 15, 942–960.
44.
TusnadyGE, and SimonI. (2001). The HMMTOP transmembrane topology prediction server. Bioinformatics, 17, 849–850.
45.
UniProt Consortium. (2015). UniProt: A hub for protein information. Nucleic Acids Res, 43, D204–212.
46.
YoungEJ. (1995). An overview of human brucellosis. Clin Infect Dis, 21, 283–289.
47.
YuCS, LinCJ, and HwangJK. (2004). Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci, 13, 1402–1406.
48.
ZviA, RotemS, Bar-HaimE, CohenO, and ShaffermanA. (2011). Whole-genome immunoinformatic analysis of F. tularensis: Predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response. PLoS One, 6, e20050.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
